Developer · United States
Embera NeuroTherapeutics, Inc.
Privately held clinical-stage specialty pharmaceutical company (Shreveport, Louisiana and Boston) focused on addiction; a portfolio company of the Biomedical Research Foundation's Entrepreneurial Accelerator Program. Sole disclosed asset is EMB-001 (metyrapone/oxazepam), licensed from LSU Health Shreveport. No public company news located after June 2021.
1compound
2programs
2indications
Phase 2lead asset
Pipeline (1)
- Cocaine use disorderPhase 2Unknown
- Tobacco use disorderDiscontinuedDiscontinued
Deals & partnerships
- Jun 30, 2021FinancingEmbera discloses $1.3 million financing from current investorsThe 2021-06-30 release states the Phase 2a smoking study was funded by a $1.3 million financing from current investors, with drug manufacturing supported by a Foundation for a Smoke-Free World grant.
- Jun 2020FinancingEmbera completes $1.2 million Series B financing$1.2M Series B from current investors, completed June 2020, to support operations through completion of both Phase 2 studies (cocaine use disorder and smoking cessation).
Catalysts · 0 upcoming · 1 reported
Recently reported
- 2026-09-21missed
EMB-001 (metyrapone/oxazepam)forCocaine use disorderRegistry results
Phase 2 EMB-001 in cocaine use disorder misses primary endpoint: continuous abstinence weeks 11-13 in 2/41 (EMB-001) vs 0/41 (placebo), p=0.092.
Recent activity
- Sep 21, 2026ReadoutEMB-001 (metyrapone/oxazepam)·Cocaine use disordermissedPhase 2 EMB-001 in cocaine use disorder misses primary endpoint: continuous abstinence weeks 11-13 in 2/41 (EMB-001) vs 0/41 (placebo), p=0.092.source ↗
- May 1, 2023Phase changeEMB-001 (metyrapone/oxazepam)·Tobacco use disorderDiscontinuedNCT04933916 terminated, why stopped: 'Business decision' (16 enrolled). Inferred program discontinuation; no formal company statement.source ↗
- Oct 15, 2022Phase changeEMB-001 (metyrapone/oxazepam)·Cocaine use disorderPhase 2Phase 2 study completed (primary completion 2022-07-27, study completion 2022-10-15). No follow-on trial or company statement since; results (primary not met) posted 2026-09-21.source ↗
- Jun 10, 2021Phase changeEMB-001 (metyrapone/oxazepam)·Tobacco use disorderPhase 1/2Open-label smoking cessation study NCT04933916 started (registered Phase 1/Phase 2; company calls it Phase 2a). First subject dosed announced 2021-06-30.source ↗
- Jul 29, 2020Phase changeEMB-001 (metyrapone/oxazepam)·Cocaine use disorderPhase 2Phase 2 NCT04501874 started; first subjects dosed announced 2020-08-31.source ↗
- Mar 1, 2015Phase changeEMB-001 (metyrapone/oxazepam)·Cocaine use disorderPhase 1First registered EMB-001 study (NCT02406066, Phase 1 SAD/MAD in smokers, NIDA collaborator) started March 2015 (month precision on the registry).source ↗
- Mar 1, 2015Phase changeEMB-001 (metyrapone/oxazepam)·Tobacco use disorderPhase 1Phase 1 SAD/MAD in otherwise healthy regular cigarette smokers (NCT02406066) started March 2015 (month precision).source ↗
Competitive landscape
Other companies developing against Embera NeuroTherapeutics, Inc.'s targets or indications.